On September 22, 2026, Viking Therapeutics reported topline results from the maintenance portion of its VK2735-102 study — the first controlled answer to the question every GLP-1 user eventually asks: what happens to the weight when the shots slow down? Subjects who stepped from weekly injections to every-other-week dosing kept 90% of their weight loss over 12 weeks. Monthly dosing held 85%. Placebo held 61%.
VK2735 is a dual GLP-1/GIP receptor agonist — the same receptor pairing as tirzepatide — and the stock moved hard on the readout because maintenance is the part of the obesity-drug story nobody has owned yet. Here is what the data shows, and what it does and does not mean for compounds actually available today.
Research-context information only. VK2735 is an investigational compound with no marketing approval anywhere; it is not available outside Viking's clinical trials. Results described here come from a company-reported topline release, not a peer-reviewed publication. This article reports what has been documented, not what should be done. Research-use-only peptides sold by vendors are not FDA-approved for human use. Consult a licensed physician for personal medical decisions.
What Viking Announced
The VK2735-102 maintenance study enrolled approximately 180 adults with obesity (BMI ≥30) and ran in two stages: a 21-week weekly-dosing induction phase, then a 12-week maintenance phase in which subjects were re-randomized to every-other-week dosing, monthly dosing, or placebo.
Induction results first. Doses escalated every two weeks to final weekly doses of 15.0, 17.5, 20.0, or 22.5 mg:
| Weekly dose | Mean weight loss at week 21 |
|---|---|
| 15.0 mg | -16.3% |
| 17.5 mg | -17.8% |
| 20.0 mg | -18.7% |
| 22.5 mg | -17.1% |
| Placebo | -0.1% |
All active arms hit p<0.0001 against placebo, and Viking reported no plateau in any cohort through week 21 — weight was still coming off when the induction phase ended. An exploratory cohort that simply stayed on 17.5 mg weekly through week 33 (n=13) reached 21.7% mean weight loss from baseline, still without plateau.
Then the maintenance phase, the actual news:
| Regimen (weeks 21-33) | Share of week-21 weight loss kept |
|---|---|
| Every-other-week VK2735 (combined) | 90% — best arm (10.0 mg) held 97% |
| Monthly VK2735 (combined) | 85% (range 82-90% across arms) |
| Placebo | 61% |
Tolerability during maintenance was, in Viking's wording, not meaningfully different from placebo: GI event rates were placebo-like, and one subject per maintenance arm discontinued for an adverse event. During the 21-week induction only 1% discontinued for adverse events despite the accelerated two-week titration steps.
CEO Brian Lian tied the result to the molecule's long half-life and said the company plans a part 2 of the study testing oral maintenance dosing — weekly injections to build the loss, a tablet to keep it.
Why Maintenance Is the Real Story
Rebound is the documented weak point of the entire incretin class. Withdrawal extension data across approved GLP-1 drugs has consistently shown most lost weight returning within a year of stopping — the pattern covered in our weight-regain-after-stopping breakdown. Until now the industry's answers were "stay on the weekly drug indefinitely" or switch-down strategies tested piecemeal, like maritide's monthly injection switch trial and orforglipron as a post-injection maintenance pill.
VK2735-102 is the first randomized readout in a GLP-1/GIP agonist built specifically to measure dose-frequency step-down, and the placebo arm makes the comparison unusually clean: same induction, same clinic visits, only the maintenance regimen differs. Twelve weeks is a short window — placebo subjects still held 61%, and published withdrawal-extension studies describe the regain curve steepening in the months that follow — but the 24-to-36-point gap between placebo and active maintenance arms emerged by week 4 and widened from there.
The commercial logic is obvious. An every-other-week or monthly regimen halves or quarters the injection burden and the drug volume. Community discussion around approved incretin drugs has long described interval-stretching as an informal cost-management tactic; this is the first controlled evidence that a reduced-frequency regimen can hold results — for this molecule. Viking's half-life argument is specific to VK2735, and no equivalent controlled step-down data exists for semaglutide or tirzepatide.
What This Means for Peptide Buyers Today
VK2735 itself is not buyable. It is a Phase 3 compound, it is not stocked by research vendors, and anything labeled "VK2735" outside a Viking trial has no verifiable provenance. The read-through is about the mechanism — GLP-1/GIP dual agonism — which is already on the market and in the research channel.
Vendor links below are affiliate partnerships — we may earn a commission at no added cost to you.
- Tirzepatide targets the same GLP-1/GIP receptor pair, though its trial record is its own — VK2735's maintenance results don't transfer to a different molecule. Research vendors stock it in lyophilized form; compare tirzepatide vendors and current coupons for COA-verified pricing, and see the tirzepatide dosing guide for what its own trials reported on weekly dosing and titration.
- Retatrutide remains the most-watched research peptide in the weight-loss category — a triple agonist that adds glucagon on top of the GLP-1/GIP pairing. Compare retatrutide vendors and the retatrutide buying guide for the current market.
- Semaglutide is the single-receptor benchmark all of this is measured against. Compare semaglutide options.
For active discount codes across the category, see the full vendor deals page.
